Get your free ETF data sample from our comprehensive offerings. Start your free trial

Help us improve your experience. Please confirm your investor type:

ETF What's Up

Don’t Miss a Move in the ETF Market

Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.

ETF What's Up

You may unsubscribe at any time by clicking the “unsubscribe” link within the emailed newsletter. By signing up, you agree to our Privacy Policy and Terms and Conditions.

227540

Mirae Asset TIGER 200 HEALTH CARE ETF

Passive ETFEquity
Not rated

The 227540 Exchange Traded Fund (ETF) is provided by Mirae Asset Global Investments. It is built to track an index: KOSPI 200 Health Care Sector Index. The 227540 ETF provides physical exposure, so by buying it you actually own parts of all the 14 underlying holdings. This share class generates a stream of income by distributing dividends.

Advertisement

Advertisement

₩19,355
+₩115 (+0.60%) today
12:00 AM 09/04/26 Closed
1D price range
₩19,190₩19,510
52W price range
₩16,840₩25,765
YTD Perf.
-14.19%
YTD Flows
Annualized volatility
Fund AuM
€20M
Share class AuM
€20M
TTM Yield
Tracking Error
Tracking Difference
ISIN
KR7227540002
TER
0.4%
Inception date
9/23/2015
Replication method
Dividend policy
Compare similar ETFs
API
PerformanceDec 30, 2025 - Sep 2, 2026
-30%-20%-10%0%10%JANMARMAYJULSEP
Flows
Join for free to unlock
Data as of 07/31/26
Healthcare
99.79%
Unavailable
0.21%
Latest 227540 news

No content available for this fund

FAQ about 227540

227540 is a Passive ETF. This ETF provides exposure to Large Cap South Korean Health Care Equities.
227540 tracks the KOSPI 200 Health Care Sector Index - KRW, through a full replication replication method.
227540 carries a total expense ratio (TER) of 0.4%, indicating the annual cost for holding the fund.
227540 was introduced to the market on September 23, 2015. It trades on South Korea, among other exchanges
Mirae Asset TIGER 200 HEALTH CARE ETF, 227540, is provided by Mirae Asset Global Investments. Learn more about Mirae Asset Global Investments here.
227540 oversees €20M in assets as of September 2, 2026.
227540 follows a distributing dividend policy, meaning it pays out income to investors. As of September 2, 2026, its 12-month trailing yield was 0.46%.
As of July 31, 2026, 227540 has significant geographic allocations in Republic of Korea.
As of July 31, 2026, 227540 focuses largely on Healthcare.
As of July 31, 2026, 227540 holds 14 positions in its portfolio, with 99.79% of assets concentrated in its top 15 holdings.
As of July 31, 2026, 227540 top three holdings include SAMSUNG BIOLOGICS Co., Ltd., Celltrion, Inc. and Yuhan Corp..
The base currency of 227540 is KRW.
Data as of 07/31/26
SAMSUNG BIOLOGICS Co., Ltd.
23.18%
Celltrion, Inc.
21.60%
Yuhan Corp.
13.99%
SK Biopharmaceuticals Co., Ltd.
9.84%
Hanmi Pharmaceutical Co., Ltd.
6.69%
Samsung Epis Holdings Co., Ltd.
6.59%
HANALL BIOPHARMA Co., Ltd.
4.91%
Hanmi Science Co., Ltd.
3.20%
SK bioscience Co., Ltd.
2.79%
GC Biopharma Corp.
1.97%

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:
  • More fund data
  • Compare up to 3 funds
  • More screener filters
  • Edit screener columns from 100+ metrics
  • Watchlists for saving your research
  • Portfolio construction and analysis
  • Personal dashboard for live monitoring

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight